ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Recro Pharma Inc

Recro Pharma Inc (REPH)

2,09
0,00
(0,00%)
Fermé 08 Février 10:00PM
0,00
0,00
(0,00%)
Après les heures de négociation: -

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

Dernier
2,09
Prix Achat
1,99
Prix Vente
2,10
Volume échangé
-
0,00 Fourchette du Jour 0,00
0,00 Plage de 52 semaines 0,00
Cap du marché
Clôture Veille
2,09
Ouverture
-
Dernière Transaction
Dernière heure de transaction
Volume financier
-
VWAP
-
Volume moyen (3 m)
-
Actions en circulation
104 788 000
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-16,50
Bénéfice par action (BPA)
-0,13
Chiffre d'affairess
94,64M
Bénéfice net
-13,27M

À propos de Recro Pharma Inc

Recro Pharma Inc is a contract development and manufacturing company. The company is engaged in the development, formulation, regulatory support, manufacturing, and packaging of oral solid dose drug products. Recro Pharma Inc is a contract development and manufacturing company. The company is engaged in the development, formulation, regulatory support, manufacturing, and packaging of oral solid dose drug products.

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Siège social
Exton, Pennsylvania, USA
Fondé
-

REPH Dernières nouvelles

Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and Transformation

With Expanded Industry Expertise, Enhanced Service Offerings and Bi-Coastal Operations, Company Now Optimally Positioned to Support Customers’ Goal of Delivering Impactful Medicines to Society...

Recro Reports Fourth Quarter and Year End 2021 Financial Results

Recorded Q4 Revenue of $22.3 Million; Full Year Revenue of $75.4 Million More than Tripled Customer Base in 2021; Significantly Diversified Clientele Grew Organic New Business by 63% in 2021;...

Recro Reports Progress Towards Launching Fill/Finish and Lyophilization Capabilities at San Diego Facility

SAN DIEGO, Calif. and GAINESVILLE, Ga., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to...

Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022

SAN DIEGO and GAINESVILLE, Ga., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving...

Recro Wins $1.5 Million Formulation Development and CGMP Manufacturing Contract to Support Clinical Development of Topical Treatment for Skin Cancer Prevention

SAN DIEGO, and GAINESVILLE, Ga., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving...

Recro Appoints Eduardo Uribe as Head of Quality for Recro San Diego

SAN DIEGO and GAINESVILLE, Ga., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving...

Recro Reports Inducement Grants For New Staff

SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...

Recro to Present at H.C. Wainwright BioConnect 2022 Conference

SAN DIEGO and GAINESVILLE, Ga., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving...

Recro to Present at Stephens Annual Investment Conference

SAN DIEGO and GAINESVILLE, Ga., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving...

Recro Reports Third Quarter 2021 Financial Results

Acquisition of IriSys, Inc. Significantly Expands Customer Pipeline, Facilities and Capabilities Annual Revenue Guidance Increased to between $74 and $76 million Recorded Q3 2021 Revenues of $18.2...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

REPH - Frequently Asked Questions (FAQ)

What is the current Recro Pharma share price?
The current share price of Recro Pharma is US$ 2,09
How many Recro Pharma shares are in issue?
Recro Pharma has 104 788 000 shares in issue
What is the market cap of Recro Pharma?
The market capitalisation of Recro Pharma is USD 219,01M
What is the 1 year trading range for Recro Pharma share price?
Recro Pharma has traded in the range of US$ 0,00 to US$ 0,00 during the past year
What is the PE ratio of Recro Pharma?
The price to earnings ratio of Recro Pharma is -16,5
What is the cash to sales ratio of Recro Pharma?
The cash to sales ratio of Recro Pharma is 2,31
What is the reporting currency for Recro Pharma?
Recro Pharma reports financial results in USD
What is the latest annual turnover for Recro Pharma?
The latest annual turnover of Recro Pharma is USD 94,64M
What is the latest annual profit for Recro Pharma?
The latest annual profit of Recro Pharma is USD -13,27M
What is the registered address of Recro Pharma?
The registered address for Recro Pharma is 1 E. UWCHLAN AVE, SUITE 112, EXTON, PENNSYLVANIA, 19341
What is the Recro Pharma website address?
The website address for Recro Pharma is www.societalcdmo.com
Which industry sector does Recro Pharma operate in?
Recro Pharma operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
MGOLMGO Global Inc
US$ 0,4191
(126,54%)
780,33M
CDTConduit Pharmaceuticals Inc
US$ 2,831
(82,65%)
140,32M
GSIWGarden Stage Ltd
US$ 0,79
(78,73%)
215,16M
TOIIWOncology Institute Inc
US$ 0,033
(58,88%)
7,27k
CYTHCyclo Therapeutics Inc
US$ 1,19
(54,55%)
72,39M
FTELFitell Corporation
US$ 2,70
(-57,01%)
2,3M
SGBXSafe and Green Holdings Corporation
US$ 0,6401
(-44,82%)
5,65M
NKLANikola Corporation
US$ 0,4432
(-41,10%)
52,44M
PLRXPliant Therapeutics Inc
US$ 7,785
(-34,85%)
6,43M
LIPOLipella Pharmaceuticals Inc
US$ 3,08
(-33,76%)
2,2M
MGOLMGO Global Inc
US$ 0,4191
(126,54%)
816,34M
RIMEAlgorhythm Holdings Inc
US$ 0,0169
(-20,66%)
274,2M
NVDANVIDIA Corporation
US$ 129,84
(0,90%)
228,19M
GSIWGarden Stage Ltd
US$ 0,79
(78,73%)
219,63M
BHATBlue Hat Interactive Entertainment Technology
US$ 0,0537
(14,74%)
212,27M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock